Not All Generic Concerta Is Created Equal
| Autor: | Andrea D. Boan, Mary C. Kral, Michelle D. Lally |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Pediatrics Adolescent Administration Oral Osmotic controlled-release oral delivery system Parent ratings Oros methylphenidate Food and drug administration 03 medical and health sciences 0302 clinical medicine 030225 pediatrics medicine Drugs Generic Humans Adhd symptoms Child Psychiatry Therapeutic equivalence Brand names Methylphenidate business.industry 030227 psychiatry Treatment Outcome Therapeutic Equivalency Attention Deficit Disorder with Hyperactivity Pediatrics Perinatology and Child Health Central Nervous System Stimulants Female business medicine.drug |
| Zdroj: | Clinical Pediatrics. 55:1197-1201 |
| ISSN: | 1938-2707 0009-9228 |
| Popis: | Treatment effectiveness between equivalent doses of non-OROS (osmotic controlled release oral delivery system) methylphenidate ER and OROS methylphenidate ER (brand name Concerta) was examined in a clinical case series of children and adolescents followed for treatment of attention-deficit/hyperactivity disorder (ADHD). The Conners-Third Edition: Parent Rating Scale was used to compare ADHD symptoms when patients were taking non-OROS versus OROS at follow-up visits. A repeated-measures mixed-model approach was used to compare treatment effectiveness. The entire sample (N = 14) demonstrated a reduction in the mean score on the Inattention Scale from clinically significant (T-score > 65) to not clinically significant (T-score < 65) when patients were changed from non-OROS to OROS at the same dosage (mean T-score reduction = 23, p < .0001). The reduction in mean T-score after changing from non-OROS to OROS at the same dosage is indicative of improvement in symptoms of ADHD. Results provide empirical support for US Food and Drug Administration concerns regarding the therapeutic equivalence of non-OROS versus OROS for the treatment of ADHD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|